Telomerase activity was inhibited in a dose and time-dependent manner with the treatment of cisplatin for 24, 48, or 72 h in a concentration ranged from 0.8 to 50 μM in BEL-7404 human hepatoma cells. There were no changes in expression pattern of three telomerase subunits, its catalytic reverse transcriptase subunit (hTERT), its RNA component (hTR) or the associated protein subunit (TP1), after cisplatin treated for 72 h with indicated concentrations. Mean telomere lengths were decreased by the cisplatin treatment. Cell growth inhibition and cell cycle accumulation in G 2 /M phase were found to be correlated with telomerase inhibition in the present study, but percentages of cell apoptosis did not change markedly during the process.
INTRODUCTION
Primary hepatocellular carcinoma (PHCC), one of the most common malignancies in the world, is an aggressive cancer. The mean survival time from establishment of diagnosis is only about 4 months (2 months if the diagnosis is made late). It causes about 250,000 deaths annually [1] . Therefore, PHCC with a high fatality rate and short disease period has been one of the major health problems in the world.
Up to now, chemotherapy is one of the most efficient strategies in PHCC treatment, especially for unsectable patients. Cisplatin is a key chemotherapy agent in the treatment of PHCC, binding directly to DNA [2] . It has been suggested that cisplatin is activated intracellularly by the generation of a positively alkylating activity and inhibits DNA synthesis by altering the DNA template [3] .
Telomeres, the tandam repeats of DNA, form the end of eukaryotic chromosome, comprising a G-rich strand and a complementary C-rich strand. The sequence of a repeating unit of human telomeres is 5'-TTAGGG-3'. Telomeric DNA shorten about 50-200 bp per doubling in normal human cells [4] . Human telomerase is a ribonucleoprotein complex, composed of a catalytic reverse transcriptase subunit (hTERT), an RNA component (hTR) that serves as a template for the synthesis of telomeric repeats, and an associated protein subunit (TP1) [5] [6] [7] . It adds telomeric repeats to the 3' end of telomeric DNA. This telomere stabilization by telomerase can lead to unlimited cell proliferation. It was reported that PHCC exhibited a high incidence of telomerase activity and that telomerase activity increased in accordance with degree of histological undifferentiaton of PHCC but was absent in normal liver tissue [8] , [9] . However, the nship between the treatment efficiency of cisplatin and telomerase activity in PHCC has not yet been elucidated. Here, we investigated the effects of cisplatin on the telomerase activity and telomere length in BEL-7404 human hepatoma cells.
MATERIALS AND METHODS
Cell and culture condition BEL-7404 human hepatoma cell line cells from Cell Bank of Chinese Academy of Sciences [10] , were cultured in RPMI-1640 medium (Gibco) supplemented with 10% heat-inactivated newborn calf serum, at 37 in a humidified CO 2 incubator containing 5% CO 2 and 95% air.
Drug
Cisplatin (Sigma) was dissolved in RPMI-1640 to the final concentration of 5 m M and stored at 4 .
Assessment of cell proliferation
MTT assay was conducted to determine the cell proliferation [11] . Cells were seeded at 1×10
4 cells /well in a 96-well plate and incubated overnight. The drug was added to the final concentration ranged from 0.8 mM to 50 mM and treated for 24, 48 or 72 h. Following culture, the cells were incubated with 800 mg/L 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT, Sigma). Four hours later, 10% sodium dodecyl sulphate-5% isobutanol-0.12% hydrochloric acid solution was added to solubilize the formazan product. The plate was then incubated at 37 for another 12 h. The absorbance at 570 nm was measured with a model 550 microplate reader (Bio-Rad). Percentage of cell growth inhibition was expressed as: (A-B)/A×100%, where A was the absorbance value from control cells and B was the absorbance value from experimental cells.
Telomerase assay
Telomerase activity was assayed using PCR-based telomeric r epeat amplification protocol (TRAP) assay as previously describe d [12] . Cells were collected and washed with PBS, lysed in 1×3-[ ) and 2 units Taq DNA polymerase (Promeg a) were added. The reaction mixture was then subjected to 28 PC R cycles: 94 for 30s and 60 for 30s. PCR products were sepa rated by electrophoresis on 12% nondenaturing polyacrylamide g els and stained with SYBR Green I (FMC) for 15 min, visualized a nd analyzed by UVP system. In every experiment, a negative con trol (1 CHAPS lysis buffer) was included. All of experiments wer e repeated at least twice.
The relative telomerase activity was quantified by the formula:
Where TP = total product, A = total intensity of telomerase product (50 bp, 56 bp, 62 bp...), and B = intensity of internal control (36 bp).
RT-PCR
Total cellular RNA was extracted from cells using Trizol (Life Technologies, Inc.) according to the instructions of the manufacturer. In each reaction, 1 mg of total RNA was reverse transcribed into cDNA using M-Mlv reverse transcriptase (Promega). Primer sets used to amplify specific sequences were 5'-CGGAAGAGTGTCTGGAGCAA-3' and 5'-GGATGAAGCGGAGTCGGA -3' for hTERT; 5'-TCTAACCCTAACTGAGAAGGGCGTAG -3' and 5'-GTTTGCTCTAGAATGAACGGTGGAAG -3' for hTR; 5'-TCAAGCCAAACCTGAATCTGAG -3' and 5'-CCCGAGTGAATCTTTCTACGC-3' for TP1; 5'-GTGGGGCGCCCCAGGCACCA -3' and 5'-GTCCTTAATGTCACGCACGATTTC -3' for β-actin. The PCR conditions of hTERT and TP1 were 94 , 45s; 60 , 45s; 72 , 90s for 31 and 29 cycles, respectively. And the PCR conditions of hTR and b-actin were 94 , 45 s; 55 , 45s; 72 , 90s for 28 and 22 cycles, respectively [5] .
Telomere length assay
Genomic DNA samples were prepared as described [13] . Cells were lysed and proteins were digested in 10 mM Tris-HCl (pH 8.0), 100 mM NaCl, 25 mM EDTA, 0.5% SDS, 0.1 mg/ml proteinase K at 48 overnight. Following two extractions with phenol and one with chloroform, DNA was precipitated with ethanol and dissolved in 10 mM Tris-HCl (pH 8.0) and 1 mM EDTA (TE). Telomere length was detected using TeloTAGGG telomere length assay (Roche) according to the manufacturer s protocol. For each sample, 1 mg of genomic DNA was digested with Rsa I/Hinf I (Sigma), separated on a 0.8% agarose gel, transferred to a nylon membrane (Amersham Hybond-N + ), and hybridized with a telomere specific digoxigenin (DIG)-labeled probe, incubated with anti-DIG-alkaline phosphatase and detected by chemiluminescence. The blotted signal was divided into 30 equidistant intervals from 1.9 to 21.2 kilobases to calculate mean telomere length (terminal restriction fragment, TRF) using the formula TRF = (ODi) / (ODi/Li), where ODi was the chemiluminescent signal and Li was the length of the TRF fragment at position i [14] .
Flow cytometry analysis of cell cycle and apoptosis
The cells were harvested and resuspended in the solution containing 40 mM sodium citrate, 250 mM sucrose and 5% DMSO. The suspension was stored at -20 for 20 min , then thawed rapidly at room temperature and centrifuged to collect the cells. The cells were resuspended in a solution containing RNase A (5×10 4 unit/g, 50 mg /L) and 20 mg/L propidium iodide (PI). The cell cycle distribution and apoptosis were determined by the fluorescence of individual cells measured by flow cytometry [15] .
RESULTS

Effect of cisplatin on telomerase activity
The IC 50 concentration of cisplatin was 12.5 mM, calculated by growth inhibition of BEL-7404 human hepatoma cells treated with twelve different concentrations of cisplatin for 72 h (data not showed). Based on this concentration, cisplatin concentrations used in experiments were selected as follows: 50, 25, 12. 5, 3.5 and 0.8 M. Telomerase activity of BEL-7404 human hepatoma cells was inhibited in a dose and time-dependent manner with cisplatin treated for 24, 48 or 72 h in a concentration ranged from 0.8 to 50 M (Fig 1A and Fig 1B) . To analyze telomerase inhibition on gene expression level, the expression of three telomerase subunits mRNA, hTERT, hTR and TP1, was assayed after cisplatin treated for 72 h in a concentration ranged from 0.8 to 50 M. Results showed that the expression pattern of these three subunits mRNA did not change with cisplatin treatment (Fig1C) . 
Effect of cisplatin on mean telomere length
Mean telomere length of BEL-7404 human hepatoma cells was decreased by the cisplatin treatment for 24, 48, or 72 h in a concentration ranging from 0.8 to 50 μM. However, telomere shortening in cisplatin treated cells was independent of time or dose in the present study. The shortened mean telomere length ranged from 3.1 to 4.1Kbp compared with 4.2 Kbp of cell control. The telomere length assay was repeated four times and the results of all experiments showed the same pattern of telomere shortening. Results of two typical experiments were showed here (Fig 2) .
Effects of cisplatin on cell growth and cell cycle distribution
Cell growth and cell cycle distribution during cisplatin treatment were investigated to correlate these effects with telomerase inhibition or telomere shortening. Cell growth was inhibited in a dose and time-dependent manner by cisplatin treatment with indicated time and concentration, analyzed by MTT assay (Fig 3A) . After cisplatin exposure, the cell cycle of treated cells was arrested at G 2 /M phase (Fig 3B) . The percentages of cell apoptosis in general did not change markedly during the treatment (Fig 3C) , despite a few points showing increased apoptosis, but repeated experiments showed that the increased points were random, indicating that it might be due to experimental error.
DISCUSSION
Cisplatin causes DNA strand breaks especially at guanine residues. Burger et al showed that cisplatin reduced telomerase activity in testicular tumor cells for the first time [16] . However, the opposite observation was presented by Ku et al who found no effect of cisplatin on telomerase activity in nasopharyngeal cancer cells [17] . Recently, Akeshima et al reported similar result as Ku et al in ovarian cancer cells [18] . In the present study, we found telomerase activity inhibition by cisplatin in BEL-7404 human hepatoma cells. We assume that telomerase inhibition by cisplatin may be cell type specific.
Burger et al suggested that telomerase inhibition by cisplatin was the results of its effects on gene transcription based on decreasing in hTR expression in testicular tumor cells [16] . But Akeshima et al demonstrated that hTERT expression did not change with time after cisplatin treatment in ovarian cancer cells [18] , and Lin et al reported the increasing in hTERT mRNA and protein during cisplatin treatment [19] . Here, we found no changes in expression level of hTR, hTERT or TP1 mRNA in BEL-7404 human hepatoma cells during cisplatin treatment. Abundant evidences indicate that the regulation of telomerase is multifactorial in mammalian cells and involves telomerase gene expression, post-translational protein to protein interactions, and protein phosphorylation [20] . We assume that telomerase activity is inhibited by cisplatin via indirect pathway based on the present study.
Telomere loss by cisplatin treatment was reported for the first time in Hela cells which had very long telomere (about 20 Kbp) by Ishibashi et al [21] . The formation of intrastrand G-Pt-G adducts was suggested to account for the shortening of telomere. In this study, we showed the decrease of telomere in BEL-7404 human hepatoma cells which telomeres were very short in comparison with normal cells or other cancer cells (e.g. Hela cells), and this shortening of telomere may be more effective in destroying of telomere function.
Many reports showed that telomerase activity was associated with cell growth [22] . Recently, telomerase activity inhibited by cisplatin was found correlated with cell growth inhibition by Faraoni et al and Terashima et al [23] , [3] . Our observation also confirmed above reports.
Telomerase inhibition was found to correlate with cell cycle accumulation in G 2 /M phase in SW480 colon carcinoma cells by doxorubicin treatment [24] . However, later reports revealed that telomerase inhibition was correlated with the increase of cell death instead of G 2 /M phase cell cycle accumulation [25] . Here, through flow cytometry, we found in comparison with cell control, cell apoptosis did not increase markedly in treated cells while cell cycle significantly a c c u m u l a t e d i n G 2 / M p h a s e . R e s u l t s o f electromicroscopy also confirmed the above observation (data not shown). Our previous study also showed that inhibition of telomerase activity by telomerase RNA component antisense oligonucleotide arrested cell cycle at G 2 /M phase in BEL-7404 human hepatoma cells [26] . Based on the above observation, we deduce that telomerase inhibition is correlated with cell cycle accumulation in G2/M phase but not with cell apoptosis increasing. Our other study by using doxorubicin in BEL-7404 human hepatoma cells also showed the same relationship between telomerase inhibition and G2/M phase cell cycle accumulation.(data not shown) Previously, Ishibashi et al demostrated that telomere loss correlated with cell apoptosis induction in Hela cells [21] . But present study found no correlation between shortening of telomere and induction of apoptosis. In our previous study, we found that apoptosis was induced in BEL-7404 human hepatoma cells when mean telomere length decreased to about 1.7 Kbp [27] . In present investigation, mean telomere length did not reach to such critical length, consistent with our previous observation that apoptosis was not induced by cisplatin in BEL-7404 human hepatoma cells with indicated treatment.
In conclusion, in BEL-7404 human hepatoma cells, telomerase activity was inhibited by cisplatin in a dose and time-dependent manner, and mean telomere length was decreased by the treatment. Cell growth inhibition and cell cycle accumulation in G2/ M phase were found to be correlated with above effects during the treatment. The present study indicates that telomerase inhibition and telomere shortening by cisplatin may contribute to its possible mechanisms in efficiency of the treatment for PHCC.
